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Invasive fungal diseases (IFDs) are devastating opportunistic infections that result in significant morbidity and death in a broad 
range of pediatric patients, particularly those with a compromised immune system. Recognizing them can be difficult, because 
nonspecific clinical signs and symptoms or isolated fever are frequently the only presenting features. Therefore, a high index of 
clinical suspicion is necessary in patients at increased risk of IFD, which requires knowledge of the pediatric patient population at 
risk, additional predisposing factors within this population, and the clinical signs and symptoms of IFD. With this review, we aim to 
summarize current knowledge regarding the recognition and clinical presentation of IFD in neonates and children.
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Invasive fungal disease (IFD) affects primarily patients with 
a compromised immune system, classically children with a 
hematological malignancy, especially those with acute leuke-
mia, hematopoietic stem cell transplant (HSCT) recipients, 
solid-organ transplant (SOT) recipients, those with primary 
or acquired immunodeficiency, and premature neonates [1–3]. 
There is also an emerging appreciation of other patient groups 
at increased risk of IFD, such as those in a pediatric intensive 
care unit (PICU) [4, 5], patients who suffer a traumatic injury, 
those who have undergone surgery, particularly abdominal sur-
gery or corrective surgery for congenital heart disease [6, 7], and 
patients with an autoimmune and/or autoinflammatory condi-
tion treated with immunomodulatory agents [8, 9]. Because the 
clinical disease phenotype is a result of the interaction between 
a fungal pathogen and the individual host immune response, 
a variety of disease presentations, determined mainly by the 
nature of the immune impairment, can be seen [10]. Knowledge 
of the clinical signs and symptoms of IFD, additional predis-
posing risk factors, and variations in disease phenotypes across 
different at-risk patient groups is essential for enabling early 
recognition and diagnosis of IFD and, ultimately, improving 
disease outcomes.
PATIENTS WITH A  HEMATOLOGICAL MALIGNANCY 
AND TRANSPLANT RECIPIENTS
In children with a hematological malignancy or those who 
have undergone HSCT, persistent febrile neutropenia despite 
broad-spectrum antibiotic treatment is often the first and only 
clinical sign to alert the clinician to suspect an IFD [11, 12].
Risk Factors
An initial risk profile can be derived on the basis of the underly-
ing malignancy or transplant type and the specific characteris-
tics of chemotherapy. For instance, patients with acute myeloid 
leukemia, high-risk (including relapsed) acute lymphoblastic 
leukemia, recipients of an allogeneic HSCT (particularly from 
a matched unrelated donor), and those who suffer from chronic 
or severe acute graft-versus-host disease are at particularly high 
risk of infection [1–3, 13–17]. Within the first 30  days after 
HSCT [14, 18, 19], a period of significant immunosuppression 
and profound neutropenia, patients are at the greatest risk of 
IFD. However, a second period of risk exists after neutrophil 
engraftment that coincides with acute or chronic graft-versus-
host disease and requires ongoing vigilance well beyond neu-
trophil recovery [3, 14, 20]. The risk of developing IFD after 
autologous HSCT is considerably lower than that after alloge-
neic HSCT, and underlying disease can affect the incidence of 
IFD [1, 21, 22].
IFD in children with a malignancy or after HSCT rarely 
occurs in the presence of an isolated predisposing host factor 
[17, 23]. Typically, multiple risk factors are present, such as pro-
longed neutropenia (absolute neutrophil count, ≤500/μL for 
≥10 days), high-dose corticosteroid use (≥0.3 mg/kg per day 
of prednisone or equivalent), additional immunosuppressive 
© The Author 2017. Published by Oxford University Press on behalf of The Journal of the 
Pediatric Infectious Diseases Society. This is an Open Access article distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Correspondence: A. Warris, MD, PhD, Aberdeen Fungal Group, MRC Centre for Medical 
Mycology, Institute of Medical Sciences, University of Aberdeen, and the Royal Aberdeen 
Children’s Hospital, Aberdeen AB25 2ZD, United Kingdom (a.warris@abdn.ac.uk).
Journal of the Pediatric Infectious Diseases Society  2017;6(S1):S12–21
DOI: 10.1093/jpids/pix053
Downloaded from https://academic.oup.com/jpids/article-abstract/6/suppl_1/S12/4100188/Recognition-and-Clinical-Presentation-of-Invasive
by University of Aberdeen user
on 01 September 2017
Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children • JPIDS 2017:6 (Suppl 1) • S13
therapy or chemotherapy, presence of a central venous cathe-
ter (CVC), use of parenteral nutrition, mucositis, concomitant 
bacterial infection, or preceding broad-spectrum antibiotic 
use [3, 5, 16, 23–26]. The depth and duration of neutropenia 
are associated with chemotherapy intensity, and the highest 
risk for IFD is reported during induction therapy [27, 28]. 
For instance, during induction chemotherapy to treat acute 
myeloid leukemia, the risk of invasive candidiasis (IC) is greater 
than that during subsequent chemotherapy courses (10% vs 
6%, respectively) [28]. Data regarding the effect of age as an 
additional risk factor for IFD in children with a malignancy 
are conflicting. In 2 studies, an age of >10 years was associated 
with a higher incidence of IFD [11, 28], whereas a subsequent 
study found no significant differences between younger and 
older children [29].
Data concerning risk factors for IFD in pediatric SOT recipi-
ents have been more limited. A study that included 1854 pediat-
ric heart transplantation recipients identified previous surgery 
and mechanical ventilation during transplantation as indepen-
dent risk factors for IFD in a multivariate analysis [30]. For 
children who had undergone lung transplantation, colonization 
before transplantation, transplant rejection, cytomegalovirus 
mismatch, tacrolimus treatment, and older age increased the 
risk of developing IFD [31]. In a recently published US study 
of 397 children who were undergoing liver transplantation, the 
only significant risk factor for IC identified with multivariate 
analysis was admission to an ICU before transplantation [32]. 
Children who undergo a renal transplant are considered to be 
at low risk for IFD; candidemia related to intravascular catheter 
use is the most common presentation [33, 34].
Clinical Presentation
Invasive aspergillosis (IA) and IC are the most common IFDs 
in patients with a hematological malignancy and in HSCT or 
SOT recipients [1, 11, 12, 35]. Non-Aspergillus molds, such as 
Mucorales, are being seen with increased frequency in patients 
who have received an Aspergillus-active antifungal agent before 
their IFD is diagnosed [3, 36]. As a result of effective prophylaxis 
with trimethoprim-sulfamethoxazole, Pneumocystis jirovecii 
pneumonia (PCP) is seen rarely in these patients. However, 
a diagnosis of PCP should still be considered in patients who 
receive second-line PCP prophylaxis agents that are likely less 
effective than trimethoprim-sulfamethoxazole [37].
Candidiasis
IC is identified most commonly after the isolation of yeasts on 
blood culture [38, 39]; Candida spp now represent the third 
most common cause of nosocomial bloodstream infection in 
children [40, 41]. Candida spp need to be strongly considered 
when a clinical diagnosis of sepsis or septic shock in a neu-
tropenic pediatric patient has been made, especially in the 
presence of an intravascular catheter and recent exposure to 
broad-spectrum antibiotics. However, although the isolation of 
Candida spp on blood culture is highly specific for IC, the sensi-
tivity of such cultures is low, and disseminated infection can be 
present in the absence of a positive blood culture result [42–44]. 
Indeed, approximately half of the patients with IC will not have 
a positive blood culture result, and it might be more useful to 
consider IC as 3 distinct clinical entities, that is, candidemia 
in the absence of deep-seated infection, candidemia with dis-
seminated infection, and deep-seated infection in the absence 
of candidemia [44, 45]. Dissemination can occur to almost any 
site, including the lungs, liver, spleen, kidneys, brain, eyes, and 
heart, although the symptoms of disseminated disease are fre-
quently minimal and might become apparent only on immune 
reconstitution [45–47]. However, the identification of dissem-
ination is important, because prolonged treatment might be 
required [45], and it is an independent risk factor for death in 
children with IC [48].
Candida meningitis and meningoencephalitis occur more 
frequently in children than in adults with candidemia (11.4% vs 
0.8%, respectively; P < .001) [49] and can present in the absence 
of candidemia [43]. In keeping with other manifestations of IC, 
patients are often asymptomatic; 5 (42%) of 12 children with 
Candida meningitis in 1 study displayed no symptoms other 
than fever [43]. When symptoms were present, the most com-
mon presenting feature was a reduced level of consciousness 
(50%), followed by seizures (33%), headache (25%), nuchal 
rigidity (25%), and cranial nerve palsies (17%). Skin lesions 
were also identified in one-third of the patients, which reflects 
the primarily hematogenous route of infection. Cerebrospinal 
fluid findings might be unremarkable, and the absence of cere-
brospinal fluid abnormalities does not exclude central nervous 
system (CNS) infection [43].
Ocular involvement during IC is a rare but potentially 
sight-threatening complication. The most frequent manifes-
tations are chorioretinitis and endophthalmitis [50]. Findings 
on examination can be unilateral or bilateral, and lesions typ-
ically appear as fluffy yellow-white retinal or vitreal balls with 
associated hemorrhage or vitreous haze [51]. Current practice 
guidelines from the Infectious Diseases Society of America 
recommend dilated ophthalmic examination within the first 
week of candidemia diagnosis in all nonneutropenic patients 
and within 1 week of neutrophil recovery in all neutropenic 
patients [45]. Examination findings are often minimal before 
neutrophil recovery, which explains the recommendation for 
delayed examination in neutropenic patients [45]. Information 
on visual outcomes in these patients has been limited; however, 
in 1 study, 3 of 4 children with endophthalmitis experienced 
subsequent complications that included retinal detachment and 
globe rupture [50].
Hepatosplenic candidiasis is rare in children [52], and 
only sparse information on its clinical presentation is avail-
able. Nausea and vomiting, right or left upper-quadrant pain, 
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hepatosplenomegaly, or transaminitis can alert a clinician to the 
possibility of hepatosplenic infection [53].
Other rare sites of dissemination in children with IC include 
the heart and skeleton. Candida osteomyelitis in children typ-
ically affects the femoral metaphysis with complicating septic 
arthritis in the neighboring joint. The humerus, vertebrae, and 
ribs are other potential sites of infection. Local symptoms are 
usually present and include pain, tenderness, overlying ery-
thema and edema, and limitation of movement; a majority of 
patients are febrile at presentation [54, 55]. Infective endocar-
ditis secondary to Candida sp infection can affect children with 
an underlying hematological malignancy, particularly during 
periods of immunosuppression, but is seen more commonly in 
children with preexisting heart disease. Presentation is typically 
with fever and a new heart murmur. The classical signs of endo-
carditis, such as Osler’s nodes, Janeway lesions, and Roth spots, 
are seen rarely in children [56–58].
Aspergillosis
The primary sites of IA are the lungs and the sinuses, yet only 
approximately half of the children with pulmonary IA display 
clinical signs and symptoms of respiratory infection [3, 36, 
59–61]. When present, the most commonly reported symptoms 
are cough, dyspnea, and chest or pleuritic pain [15, 36, 59, 61], 
and tachypnea and oxygen requirement are the only reported 
clinical signs [60, 61].
Clinical symptoms of fungal rhinosinusitis can include 
fever, rhinorrhea, nasal congestion, facial pain or numbness, 
and headache [60–63]. However, symptoms can be nonspecific, 
and symptomatic disease might be a late presentation [62]. In 
a recent study by Cohn et al [60], who used a screening pro-
tocol that included direct nasal endoscopy performed at the 
bedside by an otorhinolaryngologist in addition to computed 
tomography of the chest and abdominal ultrasound in children 
with persistent febrile neutropenia despite the administration 
of broad-spectrum antibiotics, sinonasal disease was confirmed 
in 13 (42%) of 31 patients. Of the patients identified, 8 (62%) of 
13 were asymptomatic, which suggests that fungal rhinosinus-
itis might be underappreciated in the pediatric oncology popu-
lation if diagnostic modalities are withheld until specific signs 
and symptoms occur.
After pulmonary and sinus disease, the most common site 
of Aspergillus infection is the brain [61, 64]; between 6% and 
15% of pediatric patients show evidence of CNS infection 
[17, 36, 59, 61, 65], and CNS symptoms are reported in up to 
half of all children with disseminated IA [66]. Multiple brain 
abscesses are the most common radiographic finding, followed 
by vasculitis and meningoencephalitis, although other more 
unusual clinical presentations, including intracerebral hemor-
rhage and hemorrhagic infarcts, have been reported also, which 
reflects the angioinvasive properties of Aspergillus hyphae [66]. 
Symptoms of brain abscess, such as headache and vomiting, are 
not typically seen in these patients. Instead, symptoms of dis-
orientation, somnolence, general malaise, focal seizures, hemi-
paresis, and cranial nerve palsies are associated more frequently 
with CNS aspergillosis and might be the primary presenting 
feature of IA [61, 64, 66].
Cutaneous involvement is far more common in children than 
in adults [17, 61], affecting between 8% and 41% of children 
with IA in various pediatric studies [17, 23, 36, 59, 61, 67]. This 
involvement can be a result of either local infection at the site of 
trauma (such as intravenous cannulas or CVC sites) or hematog-
enous dissemination. The clinical characteristics of cutaneous 
lesions vary from ulcers at intravenous sites to macules, papules, 
and nodular necrotic lesions with or without surrounding ery-
thema and cellulitis [36, 61, 67]. Lesions can appear as purpuric 
nodules in the extremities as a result of hematogenous dissem-
ination [64] and can progress to form necrotic eschars [67]. 
Isolated cutaneous Aspergillus infection has been associated with 
a more favorable outcome than those of other manifestations of 
IA [23, 24, 67, 68]. However, it is important to recognize that 
cutaneous lesions can represent the first sign of disseminated 
disease; 2 (33%) of 6 patients with clinically localized disease in a 
study by Abbasi et al [61] were found to have evidence of dissem-
inated disease at autopsy, and in a more recent study by Burgos 
et al [17], 9 (47.4%) of 19 patients with cutaneous infection also 
had infection at other sites. When skin lesions are present, they 
can provide a useful source of diagnostic specimens; almost one-
third of positive culture results in a 10-year retrospective study 
of invasive mold infections in pediatric oncology patients were 
isolated from the skin [36].
Cardiac involvement is also rare but has been reported con-
sistently in studies of pediatric IA in neutropenic patients [17, 
36, 61]. Clinical presentations include pericardial effusion, int-
racardiac thrombus, and endocarditis [17, 36, 61]
Mucormycosis
Similar to aspergillosis, the 2 primary sites of infection for 
mucormycosis are the pulmonary parenchyma and the sinuses. 
Among pediatric patients with a malignancy or those who were 
undergoing HSCT, 1 study found that the main clinical sites 
of mucormycosis were the lungs (25.6%), skin and soft tissues 
(12.8%), the paranasal sinuses/sinoorbital region (13.8%), and 
the rhinocerebral region (9.1%). Disseminated disease was pres-
ent in 46.5% of these patients, which is higher than with IA [69]. 
The presenting symptoms of mucormycosis cannot be differen-
tiated easily from those of IA and IFD caused by other molds, 
although signs and symptoms of hemorrhages and infarction 
are observed more frequently.
PATIENTS ADMITTED TO A PICU
Although PICU admission is itself a risk factor for IFD [70], 
the majority of children who develop IFD in a PICU have other 
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underlying risk factors that precede their PICU admission [71]. 
These factors include underlying malignancy, immunocom-
promise, a gastrointestinal disorder (particularly patients with 
short-gut syndrome), trauma, and surgery (particularly abdom-
inal surgery, neurosurgery, or corrective surgery for congeni-
tal heart disease) [5, 71, 72]. In addition, PICU patients often 
require CVC or urinary catheter placement and frequently 
receive broad-spectrum antibiotic treatment, parenteral nutri-
tion, and systemic steroid or other immunosuppressive treat-
ment, which further increases their susceptibility to IFD [4, 5, 
70, 71, 73].
Risk Factors
PICU patients are at risk of both IA and IC; however, IC is 
much more prevalent and has been better characterized [70]. 
Candida spp are now the third most common cause of blood-
stream infection and the most frequent cause of IFD in PICU 
patients [74]. Predictive scoring systems for IC in adult ICU 
patients exist [75, 76], and attempts were made recently to 
develop pediatric predictive scoring systems to help identify 
PICU patients with likely IC [5, 7, 73]. Zaoutis et al [73] were 
the first to attempt such a system and found that the presence 
of a CVC or a malignancy or the use of vancomycin or agents 
with activity against anaerobic organisms for >3  days in the 
preceding 2 weeks were significant independent risk factors for 
IC in PICU patients [36]. The authors developed a prediction 
model by combining the aforementioned factors (>10% risk) 
and observed a predicted probability of candidemia that ranged 
from 10.7% to 46% [73]. However, an attempt to validate the 
prediction model in a multicenter study proved unsuccess-
ful [77]. A separate predictive IC probability model for PICU 
patients, the ERICAP scoring system, was developed by Jordan 
et al [5]. It assigns points for the following clinical factors, iden-
tified in a multivariate analysis as significantly increasing the 
likelihood of IC in PICU patients and demonstrating high spec-
ificity for IC when present in combination: a pre-PICU hospital 
stay of ≥15 days; fever; thrombocytopenia; and use of parenteral 
nutrition [5]. Motta et al [7] also proposed a predictive scoring 
system for candidemia in children after surgery for congenital 
heart disease. They found the combination of a RACHS-1 (Risk 
Adjustment for Congenital Heart Surgery) (a scoring system 
that groups cardiac procedures into 1 of 6 categories on the 
basis of risk of death) score of ≥3, thrombocytopenia, and use 
of acid-suppression therapy resulted in a 58% predictive proba-
bility of candidemia. However, both scoring systems remain to 
be validated.
Another study found significant species-specific differences 
in risk factors; in particular, IC attributed to Candida albicans 
was associated significantly with chronic metabolic disease, 
gastrointestinal surgery, fever at PICU admission, and paren-
teral nutrition, whereas Candida parapsilosis–specific risk fac-
tors were previous yeast colonization, tracheostomy, parenteral 
nutrition, thrombocytopenia at PICU admission, and previous 
bacterial infection [5, 72]. Species-specific (C albicans versus 
non-albicans Candida spp) risk factors for IC in PICU patients 
were identified also in a study by Hegazi et al [78]; they found 
that the risk factors for acquiring non-albicans IC were an age of 
>1 year and isolation of a Candida species from a CVC or endo-
tracheal tube. Further investigation to validate and improve the 
proposed clinical prediction models are of utmost importance 
to enable clinicians to better identify children in the PICU who 
are at the highest risk for IC and could benefit from targeted 
prophylactic or preemptive antifungal treatment.
Clinical Presentation
Identifying IFD in PICU patients can be exceedingly difficult 
because symptoms frequently are indistinguishable from sepsis 
secondary to bacterial infection, and fever refractory to antibi-
otic treatment is the most common presenting feature [5, 72]. It 
is unfortunate that no study has addressed the clinical presen-
tation of IFD in pediatric PICU patients, aside from the specific 
populations highlighted in this review. However, the presence 
of thrombocytopenia often raises the concern of IC in PICU 
patients. Recent studies associated pronounced and prolonged 
thrombocytopenia with candidemia in PICU patients after cor-
rective surgery for congenital heart disease [5, 7] and in prema-
ture neonates [79–81]. Further investigation and validation of 
thrombocytopenia as a heralding sign of IC is warranted.
PREMATURE NEONATES
Neonates possess a number of endogenous and exogenous risk 
factors that predispose them to IFD, caused mainly by Candida 
spp [82, 83]. Few of these factors are intrinsic but instead have 
been associated with the immaturity of the immune system in 
these patients [83–85].
Risk Factors
Immaturity of the premature neonate’s epidermis and intestinal 
mucosal barriers enable Candida spp to translocate from the 
skin or gastrointestinal tract into the bloodstream [86]. Birth 
weight is correlated inversely with the incidence of IC; inci-
dences range from 4% to 16% in extremely-low-birth-weight 
infants and 2% to 5% in very-low-birth-weight infants [87–90]. 
Apart from their immunosuppressed status, premature infants 
are often exposed to several risk factors for IC inherent in the 
provision of prolonged intensive care. In particular, these risk 
factors include parenteral nutrition, mechanical ventilation, 
central venous access, proton pump–inhibiting agents, postna-
tal corticosteroid use, and broad-spectrum antibiotic exposure 
(particularly to third-generation cephalosporins and carbapen-
ems). Intestinal pathology and abdominal surgery, both com-
mon among neonatal intensive care unit patients, have been 
identified as risk factors also [87, 88, 91–96].
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Colonization with Candida spp before the onset of IC is 
common among neonates; colonization rates range from 18% to 
26% [84, 97–99]. Sources of colonization vary by Candida spp. 
For instance, C parapsilosis colonization occurs via horizontal 
transmission, typically >7 days after neonatal intensive care unit 
admission, whereas C albicans colonization occurs via vertical 
transmission in the perinatal period [100]. A recent study con-
ducted by Barton et al [101] found that chorioamnionitis and 
vaginal delivery were strongly associated with the development 
of early-onset candidiasis (at ≤ 7 days of life).
Although Candida spp are the predominant source of IFD 
in premature neonates, other fungal pathogens are sometimes 
opportunistic in this patient population. Malassezia spp are a 
group of lipid-dependent yeasts that frequently colonize the 
skin and gastrointestinal tract but are an infrequent cause of 
neonatal fungemia [102]. Infection with Malassezia furfur 
has been associated with the use of lipid infusions via a CVC 
in neonates [103]. IFD of the skin and soft tissues caused 
by molds such as Aspergillus spp and Mucorales have been 
reported infrequently. These infections have been described in 
relation to mild local trauma and skin contamination from the 
use of wooden tongue depressors, arm boards, and/or adhesive 
tapes [104–106].
Clinical Presentation
The most common presentation of IFD in premature neonates 
is a generalized sepsis that is indistinguishable from late-onset 
bacterial sepsis [107]. In a majority of premature infants with 
an IFD, infection presents around the third week of life and is 
caused predominantly by Candida spp. Almost 25% of candi-
demia infections in premature neonates are associated with a 
meningoencephalitis, even when no overt neurological symp-
toms are present [108]. Dissemination to the kidney (5%), eye 
(3%), and heart (5%) is seen, particularly in neonates with per-
sistent candidemia [109, 110]. Isolated infections in the CNS 
[111], kidneys [112], heart [113], and bones and joints [114] in 
the presence of indwelling devices have been reported. Candida 
infection of the kidneys in neonates can be complicated by the 
development of a fungal bezoar (fungal ball) and lead to urinary 
tract obstruction [115]. Neonates with IC develop thrombocy-
topenia more frequently than those with bacteremia and have 
both a lower platelet nadir and a longer duration of thrombo-
cytopenia [79–81]. In combination with the aforementioned 
existing risk factors, candidemia should be suspected in a neo-
nate with clinical signs of sepsis and new thrombocytopenia. 
Hyperglycemia is also a common feature of neonatal fungal sep-
sis and acts as a clinical predictor of IC; the odds of IC increase 
as the blood glucose level rises [87].
Infections caused by Aspergillus spp and Mucorales in neo-
nates are often localized to the skin and soft tissues and affect 
the most premature and extremely low birth weight neonates, 
who have an impaired and immature skin barrier function 
[104–106]. Clear differences in the common sites of mucormy-
cosis can be seen between premature neonates and older chil-
dren with a malignancy. Gastrointestinal (54%) and cutaneous 
(36%) diseases are the predominant phenotypes in neonates, 
whereas sinopulmonary and rhinocerebral patterns of disease 
are noted mainly in older children with a malignancy [116].
PRIMARY AND ACQUIRED IMMUNODEFICIENCY
IFD is highly unusual in the absence of impaired immunity but 
can represent the primary presenting feature of an underlying 
immunodeficiency. Therefore, the identification of IFD in an 
otherwise healthy child should prompt further investigation 
into possible immunodeficiency, and investigations should be 
targeted toward the most probable defective arm of host defense.
Risk Factors
The main risk factor for IFD in children with immunodefi-
ciency is the underlying immunodeficiency itself, and specific 
deficiencies in the host defense place the patient at risk for spe-
cific fungal pathogens [117]. Classical examples of this include 
IA with chronic granulomatous disease (CGD) and PCP in 
patients with severe combined immunodeficiency and acquired 
immunodeficiency secondary to human immunodeficiency 
virus (HIV) [118–123].
Deficiencies in T-cell immunity are the main predisposing 
factor for PCP, and patients at increased risk of infection include 
those with severe combined immunodeficiency, HIV, CD40 
ligand deficiency, nuclear factor κB (NF-κB) essential modu-
lator (NEMO) deficiency, hyperimmunoglobulin E syndrome 
(hyper-IgE) (Job syndrome), and X-linked hyperimmunoglob-
ulin M syndrome [124, 125]. Prophylaxis with cotrimoxazole is 
highly effective, and breakthrough infection during prophylaxis 
should prompt consideration of noncompliance or antimicro-
bial resistance [37].
The majority of cryptococcosis cases occur in children 
with defective cell-mediated immunity, caused mainly by HIV 
infection or a primary immunodeficiency such as hyperimmu-
noglobulin M syndrome, hyper-IgE syndrome, and GATA2 
deficiency [126, 127].
Disorders of host phagocyte function, such as CGD, place 
patients at increased risk for invasive mold infections such as 
those caused by Aspergillus spp and Mucorales. Indeed, patients 
with CGD remain at the highest lifetime risk of IA, despite 
effective antifungal prophylaxis [128–131]. Infections caused 
by Mucorales are rare and typically are seen in the setting of 
immunosuppressive treatment for inflammatory complica-
tions of CGD [132]. After infancy, IC is relatively uncommon 
in patients with CGD. However, the presence of additional risk 
factors, such as prolonged antibiotic treatment and the use of 
CVCs, places patients with CGD at increased risk for candi-
demia [131, 133].
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Although primary immunodeficiencies with impairment 
of interleukin 17 (IL-17) immunity traditionally present with 
chronic mucocutaneous candidiasis and have not been consid-
ered to confer increased risk of IFD [134], there are case reports 
of IC in such patients, including Candida endocarditis in a child 
with hyper-IgE syndrome [135] and meningoencephalitis due 
to Candida in children and adults with previously unrecognized 
CARD9 deficiency [136–138]. Therefore, consideration should 
be given to the possibility of an underlying IL-17 immunode-
ficiency, such as STAT3 or CARD9 deficiency, in a previously 
healthy child who presents with disseminated candidiasis.
Clinical Presentation
Classical PCP presents with hypoxia in excess of the degree of 
respiratory distress in a young infant (typically 3–6 months old). 
In contrast to most causes of pneumonia in infants, pyrexia and 
preceding coryzal symptoms frequently are absent. Instead, these 
children typically have a history of progressive dyspnea and dry 
cough with low-grade pyrexia, tachypnea, and hypoxia found on 
examination but an absence of adventitious sounds on ausculta-
tion [124, 139, 140]. Respiratory distress often progresses rapidly 
and necessitates significant respiratory support [124, 141].
Cryptococcosis most commonly manifests as meningoen-
cephalitis, disseminated disease, and pneumonia. Pulmonary 
cryptococcosis without dissemination is a recognized but 
unusual clinical presentation in immunocompromised children 
[142–144]. The most common presenting clinical symptoms 
and signs in a review that included 53 pediatric patients were 
headache (79%), fever (77%), vomiting (70%), and neck pain 
and/or nuchal stiffness (49%). Hydrocephalus was reported for 
6 patients [145]. It is notable that 26% of the children in this 
Brazilian study had no predisposing condition, and only 25% 
of the children had an underlying diagnosis of acquired immu-
nodeficiency syndrome. The average age of the children was 
7.7 years (range, 0–16 years), and only 5.6% were <2 years of age 
[145]. Other studies have found a comparable age distribution, 
with cryptococcosis occurring more frequently in middle child-
hood (6–12 years) and rarely appearing during the first 2 years 
of life [146, 147]. The most recent series of pediatric crypto-
coccosis came from a national survey of Colombian children 
<16 years of age [148]. Twenty-four percent of the children were 
HIV positive, and their mean age was 8.4 years, which is compa-
rable with that in previously published studies [145–147]. In the 
Colombian series, neurocryptococcosis (87.8%) was most com-
mon, followed by disseminated disease (12.2%). Among the 
5 patients with disseminated disease, 2 had skin involvement. 
Clinical signs and symptoms and their frequencies were similar 
to those reported from a study by Severo et al [145]. Results of 
several studies have suggested that disseminated cryptococcal 
disease is rare [145, 147, 148], although disseminated crypto-
coccosis was diagnosed in 47.8% of 23 pediatric patients in a 
case series in China. The affected organs in those 11 children 
included the lungs (n = 11), CNS (n = 7), lymph nodes (n = 10), 
liver (n = 9), and spleen (n = 7) [144]. None of the children had 
an identified immunocompromising condition, but 7 of them 
were malnourished. The differences in underlying disorders 
and geographical aspects might explain the variation observed 
in the clinical entities of cryptococcal disease.
Failure to thrive was the most common (71%) presenting 
feature of IFD in children with CGD registered in the French 
National Database for Primary Immunodeficiency over a 
25-year period [2]. The clinical presentation of IA in patients 
with CGD can be highly variable but is often indolent with min-
imal symptoms [118, 149]. Fever is reported in 61% in those 
presenting with IA [119]. However, a review of a French cohort 
of patients with CGD found that 37% reported neither fever 
nor respiratory symptoms at the time of IFD diagnosis [150], 
which is comparable with the one-third of patients with IA 
who presented to the National Institutes of Health who were 
asymptomatic at the time of diagnosis [151]. When present, 
symptoms associated with invasive pulmonary aspergillosis 
can include chest discomfort, cough (usually nonproductive), 
and progressive dyspnea, but hemoptysis is rare [119]. The 
second most common site of IA in patients with CGD is the 
bones, often with multifocal lesions; the thoracic vertebrae and 
ribs are affected most commonly [152, 153]. Clinical features 
have not been well described, but the most common manifes-
tations seem to be localized pain and tenderness, often without 
fever. Vertebral invasion is associated with signs of spinal cord 
invasion in 45% of cases. Localized brain abscesses caused by 
Aspergillus spp are considered rare [133, 154, 155]. Clinical fea-
tures vary from mild fever and headaches to seizures and local-
izing signs that mimic space-occupying lesions [119]. Other 
less common sites of Aspergillus infection include skin, lymph 
nodes, liver, and spleen [119, 133]. The clinical manifestations 
of skin infections are diverse, from erythematous plaques and 
papules to pustules and purulent ulcers, localized mainly to the 
extremities. Hepatic and splenic abscesses caused by infection 
with an Aspergillus sp typically are seen during disseminated 
infection rather than occurring in isolation [119].
Candida spp are the most common cause of fungal men-
ingitis, fungemia, and fungal lymphadenitis in patients with 
CGD [119]. Young infants with CGD (ranging from 8 weeks to 
4 months old) seem to be more prone to developing IFD caused 
by a Candida sp. Clinical signs are those of a septic infant (fever 
and irritability) sometimes associated with local signs of organ 
involvement, such as lymphadenopathy and hepatosplenomeg-
aly, or signs of CNS involvement.
SUMMARY
A wide variety of vulnerable pediatric patients are at risk of devel-
oping IFD as a consequence of either an intrinsic impairment of 
the immune system, an acquired disorder, intensive management 
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that interferes with normal immune function, or direct immu-
nosuppressive therapies. Because the clinical manifestations 
of IFD are a result of the interaction between a fungus and the 
host immune system, a variety of disease phenotypes can be 
recognized. Nevertheless, clinical signs and symptoms are often 
nonspecific and develop late during disease progression. A high 
a priori clinical suspicion is needed and should be based on the 
severity and characteristics of the immune dysfunction and the 
presence of additional risk factors. Several features separate 
pediatric IFD from those that occur in adults, and these pediat-
ric-specific features should be taken into account when develop-
ing clinical guidelines for and definitions of IFD. The European 
Organization for Research and Treatment of Cancer/Invasive 
Fungal Infections Cooperative Group and the National Institute of 
Allergy and Infectious Diseases Mycoses Study Group (EORTC/
MSG) are currently preparing a second update of the consensus 
definitions of IFD [156] in which pediatric-specific features that 
aid in disease recognition are taken into account. This important 
step forward will increase the applicability of the consensus defi-
nitions in pediatric populations and facilitate the identification of 
IFD for clinical, epidemiological, and research purposes.
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